Patients with kidney disease deserve more than outdated technology and limited options. Let’s create better treatments and better outcomes.

We are one community united by a shared belief in the lifesaving power of our collective steps. Will you contribute to our goal by walking with us? #KidneyWalk

Jessika and Joey didn’t let kidney failure stop them from falling in love or planning a wedding at the Kidney Walk. Here’s how their NKF community helped make it happen.

RT @NKF_Advocacy: TODAY is Kidney Heroes Giving Day!. Today we honor KIDNEY HEROES and the life-changing difference they make for people w….

When Patrick experienced sudden foot pain, he never imagined it would lead to a diagnosis of IgA nephropathy, or IgAN, a serious form of chronic kidney disease.

Currently, there aren’t enough donated kidneys to meet the growing demand. But xenotransplantation could help change that.

If you know someone living with immunoglobulin A nephropathy (IgAN), or Berger’s disease, this clinical research study may be an option. Learn more:

Bitcoin’s on fire at $112K! Time to flip the charts on BTCC!.Exploring Cryptocurrency with Jaren Jackson Jr.🏀.

Tell your legislator to support programs that work to increase early detection, improve outcomes, address health disparities, and develop innovative treatments for kidney patients.

This clinical research study is evaluating an investigational treatment option to potentially help manage and slow the progression of immunoglobulin A nephropathy (IgAN), or Berger’s disease. Learn more:

RESET-SLE™ is a phase 1/2 clinical trial being conducted to evaluate the effects of an investigational cell therapy, CABA-201, in patients with active lupus nephritis (LN) or active lupus (SLE) without renal involvement. Learn more about the study at

The RAINIER Study aims to reach higher summits in IgAN research. Learn more:

Today is #KidneyCancerAwarenessDay! Do you know the facts about kidney cancer? Watch our short animated videos to learn more.

Today is #FSGS Awareness Day! The New Era Act helps patients with rare kidney diseases by promoting early detection of rare and genetic kidney diseases, enhancing education of doctors and patients, and conducting more research. We need YOUR voice to push it across the finish

What do you want to know?.

Patients living with Immunoglobulin A nephropathy (IgAN), or Berger’s disease, may be eligible for a clinical research study that may help improve kidney function and slow the progression of IgAN. Learn more:

RESET-SLE™ is a phase 1/2 clinical trial being conducted to evaluate the effects of an investigational cell therapy, CABA-201, in patients with active lupus nephritis (LN) or active lupus (SLE) without renal involvement. Learn more about the study at

For 75 years, your voices, actions, and generosity have been critical to our success. Join us as we accelerate progress, drive innovation, and ensure kidney care is accessible to all. Take action: #NKF75years

Home dialysis lets people manage treatment at home with peritoneal dialysis or home hemodialysis. Is it right for you? Take this quick quiz to find out.

We’re looking for people with IgAN who are 18 or older to participate in this clinical trial. Learn more:

Catheter-related bloodstream Infection (CRBSI) can be serious. Learn the facts by visiting our CRBSI page, which has been updated to include a new interactive digital infographic.

Always curious and full of energy, Beagles turn every walk into an adventure 🐾🎉.

Whether heading to the park, relaxing in your backyard, or planning a picnic with family and friends, these five kidney-friendly foods will make the experience even better.